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Abstract
Sepsis is a complex clinical syndrome that results from a harmful or damaging
host response to infection. Sepsis is characterized by the production of proinflammatory
cytokines like TNF-a and IL-ip, which have been shown to contribute to cardiovascular
dysfunction. Annexin A5 is a phospholipid binding protein that has been shown to have
anti-inflammatory, anti-apoptotic and anti-coagulant properties. However, its effect on
cardiac function during sepsis has not been established. This thesis investigated the
effect of annexin A5 on myocardial cytokine production and cardiac function during
endotoxemia in mice. It was found that annexin A5 treatment at the onset of
endotoxemia abrogated TNF-a and IL-1P production and prevented cardiac dysfunction.
Annexin A5 likely interacts with cell-surface receptor TLR4 to inhibit myocardial
cytokine expression to protect against cardiac dysfunction during endotoxemia. These
results suggest that annexin A5 provides a novel protective role in the heart during
t

endotoxemia.

Keywords: Annexin A5, tumor necrosis factor-a, toll-like receptor-4, cardiac function,
sepsis
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Chapter 1 - INTRODUCTION
1.1

Sepsis

1.1.1

Overview o f Sepsis
Sepsis is a complex clinical syndrome that is characterized by a systemic

inflammatory response to infection. Amplification and regulation of the inflammatory
response is mediated by the innate immune system in an effort to control and remove the
foreign pathogen(s). Various cell types including monocytes, leukocytes, endothelial
cells, and even tissue cells work together in a concerted effort to prevent host damage
caused by the foreign pathogen. However, ironically sepsis is not a result of the primary
infection, but rather the amplified and deregulated host immune response (reviewed by
Cohen 2002).
In humans, sepsis is clinically identified when a patient has met 2 of the stated
criteria for systemic inflammatory response syndrome (SIRS) and there is evidence of
an infection or suspected infection (reviewed by King 2007). These criteria include body
temperature greater than 38°C or less than 36°C, heart rate greater than 90 beats/min,
respiratory rate greater than 20 breaths/min, and a white blood cell count greater than
12000/mm , less than 4000/mm , or greater than 10% immature forms (Bone et al.
1992). The majority of infections that lead to sepsis originate in the lungs, but infections
can commonly originate in the gastrointestinal tract, urinary tract, and in wounds
(reviewed by Sriskandan and Cohen 1995).
Septic shock is a subset of severe sepsis and is currently the 2nd leading cause of
death in intensive care units and the 10th leading cause of death in the United States
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(Angus et al. 2001; Martin et al. 2003). In Canada, just over 30% of patients
hospitalized with sepsis died, compared to 18% for stroke patients and 9.1% for heart
attack patients (CIHI2007; CIHI2009). Septic shock is accompanied by multiple organ
dysfunction, hypotension, and tissue hypoperfusion which can lead to death if the host is
unable to compensate for the inflammatory response (reviewed by Kumar et al. 2001).
Current therapies include anti-microbial treatments and aggressive fluid resuscitation to
modulate the host response and maintain adequate blood pressure for organ perfusion
(reviewed by Rivers et al. 2001). Yet, despite a decrease in mortality rate over the last
decade, the total number of sepsis-associated deaths continued to increase as the
incidence of sepsis rose (Martin et al. 2003). The increasing incidence will continue to
put a substantial burden on health care that reportedly spends $17 billion annually for
approximately 750,000 cases in the United States (Angus et al. 2001; Martin et al.
2003).

,

1.1.2 Myocardial Dysfunction During Sepsis
The cardiovascular system is involved in many of the sepsis-associated
mortalities resulting from refractory hypotension or cardiovascular collapse (reviewed
by Krishnagopalan et al. 2002). The majority of these deaths reflect an inability of the
cardiovascular system to adapt to the hyperdynamic state manifested during sepsis and
not a direct result of the pathology (Parker et al. 1984). Consequently, survivors have
reversible compensatory mechanisms that return cardiovascular function to normal
range within 7-10 days, while non-survivors fail to dilate the left ventricle (LV) and are
unable to maintain stroke volume and cardiac output (CO) (Parker et al. 1984).

3

Early understanding of cardiovascular manifestations of septic shock was
hindered by limitations of available technology. With the introduction of the pulmonary
artery catheter, it was shown that patients with septic shock exhibited a volume
resuscitation-dependent hyperdynamic circulatory state, consisting of high cardiac index
(Cl) and reduced systemic vascular resistance (SVR) (reviewed by Krishnagopalan et al.
2002). The strong correlation between elevated Cl and survival highlights the ability of
survivors to demonstrate compensatory mechanisms (Nishijima et al. 1973; Parker et al.
1990). It has been well established that myocardial contractility is compromised during
sepsis leading to decreased ejection fraction (EF) (Parker et al. 1984; Natanson et al.
1986). As a result, the LV is dilated in an effort to maintain stroke volume and CO in
light of decreased cardiac contractility, which increases end diastolic and end systolic
volume indexes (EDVI/ESVI) (reviewed byParrillo et al. 1990). Therefore, there is a
strong negative correlation in survivors between EDVI and EF that is not found in non
survivors (reviewed byParrillo et al. 1990).
The cause of the apparent myocardial dysfunction remained elusive for many
years. The predominant theory was that during sepsis the heart suffered from
hypoperfusion similar to other organs. Decreased SVR and an increased
hypercoagulatory state which leads to enhanced deposition of fibrin clots in small blood
vessels, contribute to inadequate tissue perfusion and subsequent organ failure
(reviewed by Cohen 2002). However, two findings by Cunnion et al. 1986 dispelled this
theory for the heart during sepsis. They showed that there was no change in coronary
blood flow and no myocardial lactate extraction, evidence that the heart’s metabolic
energy supply was not compromised (Cunnion et al. 1986). The latter was later
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confirmed by the preservation of myocardial oxygen metabolism and high-energy
phosphates supporting the suggestion that myocardial ischemia is not present during
sepsis (Hotchkiss et al. 1991; Solomon et al. 1994).
Two more theories for sepsis-induced cardiac dysfunction have also proven to be
flawed. First, although the activities of proapoptotic caspases are increased in hearts
during endotoxemia, the rate of apoptosis is too low and disproportionate to the severity
of cardiac dysfunction for apoptosis to be responsible (Carlson et al. 2005; reviewed by
Crouser 2005). Second, during sepsis neutrophil accumulation is not prevalent in the
heart like it is in other organs and it has been shown that neutrophil accumulation is not
required for cardiac dysfunction (Raeburn et al. 2002; Peng et al. 2003; Tavener and
Kubes 2006).
However, it was shown that compromised ventricular contractility, and not
structural damage, was the major cause of depression in early septic shock (Ognibene et
al. 1988). Evidence suggested the presence of humoral factors contributing to shock and
cardiac dysfunction after neonatal rat myocyte contractility was depressed when
exposed to sera from acute phase septic shock patients (Parrillo et al. 1985). Further
studies confirmed that endogenous cytokines, like tumour necrosis factor-a (TNF-a), fit
the biochemical profile of a ‘myocardial depressant substance’ that can produce many of
the same hemodynamic abnormalities seen during sepsis (Natanson et al. 1989). It has
been shown that other cytokines, like interleukin-ip (IL-ip), act synergistically with
TNF-a to directly depress cardiac function (Cain et al. 1999).
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There appear to be two distinct stages in which cardiac depression occurs after
exposure to foreign pathogens or cytokines. The early stage, which can occur within
minutes, appears to be nitric oxide (NO) independent (Yokoyama et al. 1993), while the
later stage, influential after several hours, is believed to be NO-dependent (reviewed by
Meldrum 1998). While studies have linked early myocardial depression and TNF-a
expression to NO production from constitutive nitric oxide synthase (cNOS) or
endothelial nitric oxide synthase (eNOS) (Finkel et al. 1992; Kinugawa et al. 1994; Peng
et al. 2003), it is believed that NO does not play a major role until the induction of
inducible NOS (iNOS), which produces NO in much larger amounts and doesn’t occur
until approximately 5-12 hr after induction of sepsis (Wolfard et al. 2000; reviewed by
Kumar et al. 2001).
Septic myocardial depression involves reversible attenuation of the strength of
myocyte contraction. Only 2 mechanisms can account for this change: 1) decreased
cytosolic Ca2+ release and 2) decreased myofilament sensitivity to Ca2+ (reviewed by
Kumar et al. 2001). The early stage of myocardial depression is a result of decreased
Ca2+ transient during systole through the sphingosine-dependent inhibition of ryanodine
receptors (Yokoyama et al. 1993; Oral et al. 1997). In the later stage, the induction of
iNOS by TNF-a results in increased NO levels which can react with oxygen radicals in
the cell and create peroxynitrite. Increased NO and peroxynitrite levels desensitize the
myofilament to Ca2+ leading to sustained contractile dysfunction (Goldhaber et al.
1996). Yet, the precise mechanism of cardiac depression during sepsis remains
somewhat elusive. Studies have also emphasized the importance of innate cell receptors,
adhesion molecules, and components of the complement system in regulating sepsis-
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associated cardiac depression, making a potential therapeutic method difficult to
establish (Raeburn et al. 2002; Tavener et al. 2004; reviewed by Rittirsch et al. 2008).
1.2

TNF-a and IL-ip during Sepsis

1.2.1

Overview
The defining characteristic of sepsis is the excessive production of pro

inflammatory cytokines that contribute to systemic inflammation. Cytokines such as
TNF-a and IL-ip have been implicated in the pathogenesis of myocardial dysfunction
and cardiomyocyte death in ischemia/reperfusion injury, sepsis, and chronic heart failure
(Levine et al. 1990; reviewed by Meldrum 1998).
Cytokines are a family of peptides that include peptide growth factors,
erythropoietin, transforming growth factor-P, and inflammatory cytokines (eg. TNF-a,
interleukins, interferons). Therefore, not surprisingly, they display significant functional
diversity in which TNF-a alone can activate growth-promoting effects or initiate
programmed cell death.
TNF-a is a 17 kDa pyrogen that was initially discovered as the molecule
associated with necrotizing effects in mouse tumors (Carswell et al. 1975), but it is well
established that TNF-a is an important inflammatory cytokine that contributes to a wide
range of organ pathologies (reviewed by Meldrum 1998). TNF-a remains inactive until
it is inserted into the membrane where it undergoes post-translational modification by
TNF-a converting enzyme (TACE) prior to its release into the extracellular space
(McGeehan et al. 1994). Through TNF-a receptors 1 and 2 (TNFR1, TNFR2), TNF-a
can activate receptor-associated domains like FADD and TRADD, the ‘death domain’,
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and TRAF to initiate the activation of caspases and nuclear factor-kappaB (NF-kB)
(Chinnaiyan et al. 1995; Hsu et al. 1995).
Proinflammatory cytokines act to increase their own production through
activation of transcription factors like NF-kB. IL-1J3 is produced in response to TNF-a,
but was the first cytokine shown to have a wide range of biological properties (reviewed
by Dinarello 2005). Increased expression of IL-ip has been implicated in sepsis and
rheumatoid arthritis, where treatment with a receptor antagonist decreased inflammation
(Bresnihan et al. 1998).
1.2.2

TNF-a and IL-lfi Production in the Heart During Sepsis
Traditionally, the liver and spleen are viewed as the primary sources of TNF-a

because they have large populations of macrophages, a major source TNF-a production.
In the heart however, cardiomyocytes can produce substantial amounts of TNF-a in
response to ischemia or lipopolysaccharide (LPS) (Giroir et al. 1992; Kapadia et al.
1995; Gurevitch et al. 1996; Grandel et al. 2000). Although it has been proposed that
resident macrophages and cardiomyocytes produce equal amounts of TNF-a in the
myocardium, our lab has shown cardiomyocytes to be the major source of TNF-a after
LPS exposure (Peng et al. 2003).
Cytokine production during sepsis is adaptive in the short term to fight and clear
bacteria, but becomes maladaptive after excessive or long term exposure (reviewed by
Elahi et al. 2007). TNF-a and IL-1(3 levels increase during sepsis and septic shock with
elevated TNF-a plasma levels being associated with increased mortality in septic
patients (Casey et al. 1993). However, inhibition of TNF-a has failed to demonstrate an

improvement in survival of septic patients (Abraham et al. 1995; Fisher et al. 1996).
This is likely due to multiple redundant pathways and is evidence to the complexity of
the disease.
1.2.3

TNF-a and IL-1J3 in Myocardial Dysfunction During Sepsis
The negative impact of TNF-a on cardiovascular function was first observed

during immunomodulatory therapy for cancer (Blick et al. 1987; Steinmetz et al. 1988).
Since then it was identified as a ‘myocardial depressant substance’ responsible for many
of the cardiac abnormalities observed during sepsis (Natanson et al. 1989). Additionally,
many of the biological effects of TNF-a are mirrored by IL-ip (Last-Barney et al.
1988). Synergy of actions between the cytokines can cause myocyte depression at
concentrations 50-100 times lower than required individually (Gulick et al. 1989).
Administration of TNF-a or IL-lp into animals or in vitro and ex vivo tissue
results in a concentration-dependent depression of contractility (Finkel et al. 1992; Cain
et al. 1999). TNF-a challenge in dogs simulates cardiac depression during human septic
shock (Natanson et al. 1989) and cardiac specific TNF-a over expression in mice
induces LV dilatation, reduced EF, and premature mortality (Kubota et al. 1997; Bryant
et al. 1998). Inhibition of excessive cytokine action through IL-ip receptor antagonists
or TNF-a production pathway inhibitors improves myocardial function in response to
septic shock (Wakabayashi et al. 1991; Peng et al. 2003).
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1.3
1.3.1

Innate Immune Response
Overview o f the Innate Immune Response Following Infection
The innate immune system is the body’s first line of defense against infection.

Macrophages, neutrophils, mast cells, and effector cells trigger the inflammatory
response observed during sepsis in an effort to hold the potential infection in check
(Figure 1) (reviewed by Warren 2005). Increased vascular permeability, vasodilation,
inflammation, and coagulation are initiated in a concerted attempt to isolate and remove
foreign pathogen(s) without compromising oxygen and nutrient delivery throughout the
body (Clark et al. 2007). Sepsis results when the inflammatory response is exaggerated
and becomes damaging to the host. Although deficiency of the innate immune response
is associated with an increased susceptibility to infection (reviewed by Rosenzweig and
Holland 2004), a greater threat is posed by an excessive inflammatory response
(reviewed by Smith 1994).
Innate immunity requires recognition of evolutionarily conserved pathogen
associated molecular patterns (PAMPs) associated with particular classes of pathogens.
Toll, a Drosophila receptor essential for the production of antimicrobial peptides in
response to fungal pathogens, led to the discovery of a family of mammalian
transmembrane Toll-like receptors (TLR) (reviewed by Miller et al. 2005). TLRs are
genome-encoded pattern recognition receptors (PRR) responsible for the identification
of foreign pathogens and initiation of the immune response. TLR4, the human
homologue of Drosophila Toll, is responsible for recognition of gram-negative bacteria,
which accounts for approximately 37% of sepsis-associated infections (Angus et al.
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2001; Martin et al. 2003). Gram-positive bacteria and fungi are responsible for the
remainder.

In v a sio n
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4
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Figure 1. The innate immune system is the body’s first line of defense against infection.
Innate immunity requires recognition of foreign pathogens by pathogen recognition
receptors (PRR) to initiate an immune response that involves pro-inflammatory cytokine
production in an effort to control and remove foreign pathogens from the body.
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1.3.2 Lipopolysaccharide
Lipopolysaccharide (LPS), also referred to as endotoxin, is a major element of
gram-negative bacterial cell walls and is essential for membrane structure and integrity.
The lipid A portion of LPS serves to anchor LPS in the bacterial cell wall and is the
component recognized by PRRs of the innate immune system. The presence of
endotoxins has been correlated with increased mortality and shown to qualitatively
mimic many hemodynamic, hematologic, and metabolic manifestations of sepsis
(Natanson et al. 1986; Casey et al. 1993).

Polysaccharide

Glycophospholipid

Figure 2. Diagram of lipopolysaccharide structure. Adapted from Caroff et al., 2002.
LPS is amphiphilic and consists of polysaccharide and glycophospholipid
portions (Figure 2) (reviewed by Caroff et al. 2002; reviewed by Jerala 2007). The
polysaccharide segment is hydrophilic and composed of three sections: the inner core,
outer core, and O-specific chain. Bacterial species stereotype specificity and protection
from host defence is conferred to the O-specific chain which consists of 1-8 sugar
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repeating units (reviewed by Caroff et al. 2002). The glycophospholipid segment is the
hydrophobic and negatively charged portion called lipid A. Lipid A is highly diverse
and defines the function of LPS through the varied number and length of fatty-acid side
chains (reviewed by Miller et al. 2005; reviewed by Jerala 2007). It is stabilized by
divalent cations and because of its hydrophobic nature, it serves as the anchor to the
bacterial cell wall (reviewed by Caroff et al. 2002). LPS is recognized in mammals by
TLR4, which upon activation is responsible for the production of pro-inflammatory
cytokines that characterizes sepsis and septic shock (Baumgarten et al. 2001).
1.3.3

TLR4 Signalling and LPS Recognition
TLR homologues are found in all multicellular organisms. They are traditionally

expressed on the cell surface but are also found in intracellular compartments and in the
bloodstream and tissue fluids. The principal functions of TLRs include induction of
apoptosis, opsonization, activation of proinflammatory pathways, and initiation of
complement and coagulation cascades (reviewed by Janeway and Medzhitov 2002).
Drosophila Toll was the first member of the 10-member Toll family known to
have functional similarities to human IL-1R (ie. TIR domain) because of it’s ability to
induce activation of the transcription factor NF-kB during the immune response
(reviewed by Janeway and Medzhitov 2002). NF-kB is the most important transcription
factor that regulates cytokine expression and has been shown to be activated by gram
positive and -negative bacteria, viruses, cytokines, free radicals, and oxidants (reviewed
by Zingarelli 2005). Activation of NF-kB, which involves translocation to the nucleus,
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can occur within 30 minutes of TLR activation in the myocardium (Baumgarten et al.
2001).
Macrophages are the most studied cell type in understanding LPS signalling
through TLR4. Recognition of LPS requires the help of accessory proteins like LPS
binding protein (LBP) and CD-14 to transfer LPS to the membrane and enable
interactions with TLR4, respectively (reviewed by Janeway and Medzhitov 2002). MD2 is another small extracellular protein tightly bound to TLR4, which binds directly to
LPS and is essential for LPS signalling (Shimazu et al. 1999). The precise role of these
accessory proteins remains unclear but mice deficient in any of the LPS receptor
components are more susceptible to gram-negative bacterial infection and are
hyporesponsive to LPS administration (Haziot et al. 1996; Shimazu et al. 1999; Arbour
et al. 2000).
Upon activation by LPS, TLR4 functions as a homodimer to allow its
intracellular TIR domain to interact with the adaptor molecules MyD88, TIRAP/MAL,
TRAM, and TRIF to initiate signalling (reviewed by Warren 2005). The eventual
activation of NF-kB is regulated by various signalling molecules like NOX2 (NADPH
Oxidase) and the mitogen-activated protein kinases (MAPK). Our lab has shown
previously that NOX2 and the MAPKs p38 and extracellular signal-regulated kinase
(ERK) play a pivotal role in regulating TLR4 signalling, and thus the production of
proinflammatory cytokines in cardiomyocytes (Peng et al. 2003; Peng et al. 2005).
Activation of TLR4 in cardiomyocytes correlates with increased cytokine
production (Baumgarten et al. 2001) and decreased cardiomyocyte contractility (Boyd et
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al. 2006). In addition, studies that inhibit TLR4 function through competitive inhibition
or point mutations have decreased TNF-a and IL-1J3 levels and improved myocardial
function in response to LPS (Baumgarten et al. 2001; Nemoto et al. 2002; Baumgarten
et al. 2006). Therefore TLR4-dependent cytokine production is necessary for myocardial
depression during sepsis.
1.3.5 Phosphatidylserine
Phosphatidylserine (PS) is a negatively charged phospholipid normally
asymmetrically distributed by an ATP-driven phospholipid translocase (flippase) on the
cytosolic surface of cell membranes (reviewed by Vance and Steenbergen 2005). It is
believed that PS is involved in regulating membrane charge and protein localization at
cytosol facing membrane leaflets. However during periods of stress such as apoptosis,
coagulation or anoxia, inhibition of translocase and the Ca2+-dependent activation of
scramblase result in PS translocation to the outer membrane leaflet, where it serves as a
signal to the extracellular environment (Kuypers et al. 2007).
During coagulation, PS becomes exposed after activation of the endothelium and
platelets to serve as the docking site for prothrombinase complex assembly (reviewed by
Vance and Steenbergen 2005). During apoptosis, exposed PS is known as an ‘eat me’
signal for phagocytosis by monocytes. However, while PS exposure is often used as a
marker for apoptosis (Koopman et al. 1994), it is not a determined path to apoptosis.
Exposure of PS can occur independent of apoptotic mechanisms (Balasubramanian et al.
2007) and has been shown in T-lymphocytes and myoblasts to modulate signal
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transduction and mediate cell-cell interactions without committing to apoptosis (van den
Eijnde et al. 2001; Elliott et al. 2005).

1.4

Annexin A5

1.4.1

Annexin A5 Overview
Annexin A5 is a 37kDa protein and part of a 13-member family of ubiquitously

and constitutively expressed proteins; however, no single annexin is expressed in all
cells. All members of the annexin family must satisfy two major criteria: 1) they must be
capable of reversibly binding in a Ca -dependent manner to negatively charged
phospholipids, and 2) they must contain as a conserved structural element, the ‘annexin
repeat’, a segment of some 70 amino acids (reviewed by Gerke and Moss 2002).
Annexins are soluble intracellular proteins that are freely distributed in the
cytoplasm at resting Ca2+ levels and move to the membranes when Ca2+ levels are
elevated (reviewed by Gerke et al. 2005). Interestingly, some annexins including
annexin A5 have been found to have extracellular functions even though they lack a
secretory sequence (reviewed byGerke and Moss 2002). The approximate circulating
concentration of annexin A5 is less than 5 ng/ml (Flaherty et al. 1990), and because of
its relatively small size, it is readily filtered by the kidney and only has a half-life of
roughly 15 minutes (Kuypers et al. 2007).
Although the annexin family lacks functional unity, all of the known functions
involve phospholipid membrane interactions because of their ability to bind to

16

negatively charged phospholipids. Annexin A5 has a unique ability to form a two
dimensional crystal shield on planar lipid bilayers containing negatively charged
phospholipids, in particular phosphatidylserine (PS) (Voges et al. 1994; Oling et al.
2000). This two dimensional shield is what gives annexin A5 its trade mark anti
coagulant and anti-apoptotic functions (Figure 3) (van Heerde et al. 1994; London et al.
1996; Kenis et al. 2006). In addition, annexin A5 has also been shown to be involved in
membrane scaffolding, Ca2+ signalling, and membrane-associated internalization
(reviewed by van Genderen et al. 2008). Annexin A5’s apparent ability to internalize PS
expressing membrane patches has even caused it to be proposed as a target for
intracellular drug delivery into living tumors (reviewed by Kenis et al. 2007). The
mechanism of such a phenomenon is still relatively unknown as it is independent of
traditional endocytotic pathways like those of macropinocytosis and receptor-mediated
internalization.
1.4.2 Annexin A5 Structure and Binding
Each annexin is made up of 2 principal domains: a conserved COOH-terminal
protein core, and a divergent NFL-terminal head. The COOH-terminal core consists of 4
homologous a-helices forming a slight curvature with 2 principle sides. The convex side
contains the Ca2+ and phospholipid binding sites that face the membrane when bound.
The concave side points away from the membrane and appears accessible for
interactions with the NH2-terminal domain or other binding partners (reviewed by Gerke
and Moss 2002). The variable NH2-terminal head confers the functional specificity for
each annexin as it extends along the concave side of the protein core (reviewed by
Swaiijo and Seaton 1994). The protein core forms a hydrophilic pore between the repeat
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1/4 and 2/3 modules where it is believed the NH2-terminal head may be involved in the
regulation of Ca2+ conductance through the central pore (reviewed by Gerke and Moss
1997). However, the in vivo evidence for Ca conductance is scarce, making annexin

Macrophages
Leukocytes
Coagulation Factors
Platelets
Receptor Ligands

Annexin A5
Cardiomyocyte
Endothelial Cell
Platelet
Monocyte
Microparticles

Figure 3. Schematic illustrating the known functions of annexin A5. Annexin A5 binds
to cell receptors or exposed phosphatidylserine (PS) on the surface of various cell types
like cardiomyocytes, endothelial cells, and platelets. Annexin A5 has the unique ability
to form a two-dimensional shield on cell membranes to sterically hinder cell receptor
function and PS interaction with various extracellular factors to inhibit coagulation,
apoptosis, and inflammation.
A n nexin A5

Figure Legend:
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A5’s ability to form Ca2+ channels inconclusive. The diameter of the central pore is
inconsistent with the observed conductance values and annexins lack the obvious
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exposed hydrophobic regions typical of membrane spanning proteins (reviewed by
Swaixjo and Seaton 1994; reviewed by Gerke et al. 2005). Therefore it is difficult to
assign traditional ion channel properties to the annexins.
Among the annexins, annexin A5 requires the highest Ca2+ concentration of 10
pM - 100 pM for half-maximal binding (reviewed by Gerke and Moss 1997). With Ca2+
concentration of approximately 1 mM in the circulation, any expressed PS on the cell
surface favors the rapid binding of annexin A5 (reviewed by van Genderen et al. 2008).
ha solution, annexin A5 molecules exist as monomers, but upon binding, they form
trimers to assemble a two-dimensional crystal lattice over the surface of PS-expressing
membranes (Voges et al. 1994; Oling et al. 2000). It has not yet been demonstrated
whether annexin A5 can crystallize on PS-expressing cell surfaces, but in vitro studies
using constructed phospholipid bilayers demonstrate that crystal lattice density is
dependent on PS content and Ca2+ concentration. Annexin A5’s associate with each
other through amino acid mediated protein-protein interactions (reviewed by van
Genderen et al. 2008).
The asymmetrical structure of annexin A5 may lead to membrane indentation
that could be a necessary mechanism for both Ca channel signalling and PS-dependent
membrane internalization (reviewed byKenis et al. 2004; reviewed by Gerke et al.
2005). Membrane internalization has been associated with annexin A5’s ability to
regulate cell-surface receptor expression (Ravassa et al. 2005) and interestingly, annexin
A5 has also been shown to bind to and inhibit the function of cell-surface membrane
receptors (Leon et al. 2006). In a study investigating the regulation of epithelial
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junctions in the kidney, it was found that a conserved sequence in the Nt^-terminal of
annexin A5 interacts with a leucine-rich repeat of polycystin-1 to delay the recruitment
of E-cadherin at cell-cell epithelial junctions (Markoff et al. 2007).
1.4.3 Annexin AS Function
Annexin A5 was originally identified as an anti-coagulant in the human placenta
to protect against vascular thromboembolism and recurrent pregnancy loss
(Reutelingsperger et al. 1985). Annexin A5 has been localized to the apical surface of
syncytiotrophoblasts (placentas) where removal or inhibition of annexin A5 leads to loss
of placental integrity and pregnancy loss (Wang et al. 1999). Annexin A5 has the ability
to interact with exposed PS on platelets and endothelial cells and inhibit prothrombinase
complex formation and platelet adhesion through competitive inhibition (van Heerde et
al. 1994; Galan et al. 2006; Ghosh et al. 2007). Furthermore, because of its anti
coagulant functions, connections have been made between annexin A5 expression and
the incidence of early myocardial infarction (MI) in individuals under 45 years old. A
decrease of annexin A5 was associated with early MI patients (Roldan et al. 2002) while
an increase in expression through a common polymorphism decreases the risk of early
MI two-fold (Gonzalez-Conejero et al. 2002).
However, the most commonly used function of annexin A5 is as a marker of
apoptosis. Annexin A5 can be easily conjugated with a wide range of markers to
identify exposed PS on the surface of apoptotic cells (Koopman et al. 1994; Vermes et
al. 1995). Annexin A5 has also been shown to have anti-apoptotic properties by
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inhibiting macrophage or neutrophil phagocytosis that identifies exposed PS as an ‘eatme’ signal (Krahling et al. 1999; Kenis et al. 2006; Maugeri et al. 2009).
Some annexins also have the ability to moderate inflammation by controlling
leukocyte rolling and adhesion along inflamed vascular beds (Damazo et al. 2005).
Diannexin, a recombinant human annexin A5 homodimer, provided profound anti
inflammatory protection against liver ischemia/reperfusion injury (Shen et al. 2007;
Teoh et al. 2007). Inhibition of pro-inflammatory molecule expression and recruitment
maintained microvascular circulation that dramatically improved survival in rat liver
transplants (Shen et al. 2007).

1.5

Hypothesis and Research Objectives
The role of annexin A5 in sepsis-associated inflammation has not been

previously investigated. This thesis proposes a novel function of annexin A5 as an
inhibitor of inflammation through cell-receptor signalling. The objectives of the results
presented in this thesis are to 1) identify annexin A5’s interaction with the TLR4
signalling pathway, and to 2) determine if annexin A5 provides protection against
sepsis-mediated cardiac dysfunction.
We hypothesized that annexin A5 inhibits TLR4-depedent myocardial TNF-a
expression and improves cardiac function in endotoxemic mice (Figure 4).
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Figure 4. Proposed mechanism of annexin A5 on the LPS-induced TLR4-signalling
pathway leading to TNF-a expression and myocardial dysfunction.
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Chapter 2 - METHODS
2.1

E xperim ental Protocol

Animals
The mice used in these studies were wild-type (WT) C57BL/6 (Jackson
Laboratories, Bar Harbor, ME). A breeding program was carried out at the Lawson
Health Research Institute animal care facility to produce offspring. A total of 103 adult
(3-4 months old) male mice weighing 21-26 g were studied. Eighty-seven mice were
randomly assigned to the following groups: saline (sham, n=23), recombinant human
annexin A5 (n=20), lipopolysaccharide (LPS, n=22), and LPS plus recombinant human
annexin A5 treatment group (n=22). In addition, 16 mice were used for macrophage
(n=12) and adult cardiomyocyte (n=4) studies. All animals were used in accordance
with the guidelines of the Canadian Council on Animal Care and experimental protocols
were approved by the Animal Use Subcommittee at the University of Western Ontario,
Canada.
Treatments
LPS and annexin A5 treatment time was 4 hr for all measured parameters except
for western blot samples, which were collected after 30 min (Figure 5). Western blot
samples were taken after 30 min because LPS-induced MAPK phosphorylation was not
detectable after 4 hr. The control group received intraperitoneal (i.p.) and intravenous
(i.v.) saline injections. The annexin A5 alone group received 5 pg/kg i.v. injections of
human recombinant annexin A5 (Biovision, Mountain View, CA) and i.p. saline
injections. The LPS alone group received 4 mg/kg i.p. injections of Salmonella typhosa
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LPS (Sigma-Aldrich, St. Louis, MO). The LPS+annexin A5 group received sequential
injections at the same concentrations used in the individual treatment groups (Figure 5).

LPS 4 mg/kg i.p.
Annexin A5 5 (ig/kg i.v.

i
Time

0 hr

30 min

4 hr

i

r

Western Blot Samples

Cardiac Function
TNF-a/IL-lp expression
TLR4/NOX2 expression

Figure 5. In vivo experimental protocol. Mice were separated into 4 treatment groups of
control, annexin A5, LPS, and LPS+annexin A5. The LV was collected for western blot
samples after 30 min treatment. After 4hr treatment, the LV was isolated for TLR4,
NOX2, TNF-a, and IL-lp mRNA analysis, and TNF-a and IL-ip protein expression
after 4 hr treatment. Blood samples were also collected after 4 hr for TNF-a and IL-1P
protein expression. Cardiac function was assessed after 4 hr treatment using in vivo and
ex vivo techniques.
Sample Collection
After the treatment period, the mice were sacrificed and the hearts were then
excised and the LVs were isolated and stored at -80°C. For hemodynamic assessment,
mice were anesthetized with an intramuscular (i.m.) injection of a ketamine (50 mg/kg)
and xylazine (12.5 mg/kg) mixture. Blood samples were collected by cardiac puncture
into 1.5 mL eppendorf tubes containing 10 pi of heparin (1,000 USP units/mL,
Pharmaceutical Partners of Canada Inc., Richmond Hill, ON). Plasma was obtained after
centrifugation of the blood for 10 min at 5,000 rpm.
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2.2

W estern B lo t A nalysis

Protein Isolation and Measurement
Heart tissues were homogenized in cold lysis buffer (0.5% sodium dodecyl
sulfate (SDS), 1 mM EDTA, 10 mM Tris-HCl pH 7.5) and sonicated for 10 seconds at 2
output watts. Protein concentrations were measured using a Lowry protein assay (Bio
Rad, Mississauga, ON) with bovine serum albumin (BSA) as the standard.
Concentrations were measured to allow equal loading of 60 pg protein per well.
Gel Electrophoresis
Samples were run on 10% polyacrylamide gels containing SDS. The proteins
were separated by gel electrophoresis in a blotting cell (Bio-Rad, Mississauga, ON) for
90-120 min at 100 V using a Power Pac 300 (Bio-Rad, Mississauga, ON).
Western Blot
Samples were transferred from the gel onto nitrocellulose membranes overnight
at 25 V in 4°C or for 1 hr transfer at 100 V in ice. Membranes were blocked in trisbuffered saline tween-20 (TBS-T) containing 5% non-fat dehydrated milk at room
temperature for lhr. After several washes with TBS-T, the blots were probed with
antibodies against a-actinin (anti-mouse; 1:2000, Cell Signaling, Danvers, MA) p38
(phospho-p38 - anti-rabbit; total-p38 - anti-rabbit; 1:1000, Cell Signaling, Danvers, MA)
and ERK (phospho-ERK - anti-rabbit; total-ERK - anti-rabbit; 1:2000, Cell Signaling,
Danvers, MA) for overnight at 4°C. Blots were then washed with TBS-T and probed
with horseradish peroxidase-conjugated secondary antibodies (1:2000, BioRad,
Mississauga, ON) for 1 hr at room temperature according to animal specificity of
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primary antibodies. Detection was performed using Luminol Enhancer Solution
(Thermo Scientific, Rockford, IL) detection method and signals were determined by
densitometry (FluorChem 8000, Alpha Innotech Corp., San Leandro, CA).
2.3

RN A Isolation an d R T-PCR

Tissue RNA Isolation and Measurement
Total RNA was isolated from the LV by lysing the tissue with TRIzol reagent
(Invitrogen, Burlington, ON) as previously described (Song et al. 2000; Hammoud et al.
2007). The lysate was vigorously mixed with chloroform before centrifugation at 12,000
g for 15 min at 4°C to separate the RNA in the aqueous phase of the solution.
Isopropanol was added and the sample was centrifuged at 12,000 g for 10min at room
temperature to precipitate the RNA samples. The supernatant was decanted and the
precipitated RNA pellet was washed with 75% ethanol. Ethanol was removed and the
pellet was vacuum-dried for ~5 min. The pellet was re-suspended in
diethylpyrocarbonate (DEPQ-FLO and kept at 70°C for 10 min. RNA concentration
was then quantified by measuring the absorbance at 260/280 nm using a RNA/DNA
calculator (Pharmacia Biotech, Gene Quant II, Baie d’Urfe, QC).
cDNA Synthesis
cDNA was synthesized from the isolated RNA using M-MLV reverse
transcriptase (RT) and random primers (Invitrogen, Burlington, ON). One pg of RNA
and 1 pi of random primers were mixed in DEPC-H2O. Samples were then combined
with a reverse transcriptase mix consisting of 1st strand buffer, 0.1 M DTT, 10 mM
dNTP, RNAse inhbitor, and M-MLV RT (Invitrogen, Burlington, ON). The final
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mixture was then incubated at 37°C for 2 hr. Samples were incubated at 65°C for 10 min
to inactivate the reverse transcriptase enzyme, and the cDNA was diluted with 40 pL of
sterilized H2O.
RT-PCR
Real-time PCR was conducted using SYBR Green PCR Master Mix as per
manufacturer’s instructions (ABM Inc., Richmond, BC). The oligonucleotide primers
for TNF-a were sense 5’ CCGATGGGTTGTACCTTGTC 3’ and antisense 5’
GGGCTGGGTAGAGAATGGAT 3’. The primers for IL-ip were sense 5’
ACAAGGAGAACCAAGCAACGAC 3’ and antisense 5’
GCTGATGTACCAGTTGGGGAAC 3’. The primers for TLR4 were sense 5’
CCTGGAATGGGAGGACAATCC 3’ and antisense 5’
CCATGTGTTCCATGGGCTCTC 3’. The primers for NOX2 were sense 5’
GCTGGAAACCCTCCTATGACTTG 3’ and antisense 5’
TGTACTGTCCCACCTCCATCTTG 3’. Twenty eight S rRNA was used as a loading
control using oligonucleotide primers for sense 5’ TTGAAAATCCGGGGGAGAG 3’
and antisense 5’ ACATTGTTCCAACATGCCAG 3’. All primers were purchased from
Sigma-Aldrich (St. Louis, MO). Samples were amplified for 35 cycles at Tm’s
appropriate for each primer set using MJ Research Opticon Real-Time PCR machine
(South San Francisco, CA). mRNA levels were compared to that of 28S rRNA, and the
relative amount of mRNA was obtained.
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2.4

ELISA

TNF-a and IL-lp cytokine levels were measured using separate enzyme-linked
immunosorbent assay (ELISA) Ready-Set-Go! Kits from eBioscience Inc (San Diego,
CA). Briefly, 96-well plates were incubated with anti-mouse TNF-a and IL-ip primary
capture antibody in ELISA Coating Buffer overnight at 4°C. Between each step, wells
were washed for 1-2 min ~5 times with wash buffer (PBS + 0.05% Tween-20). Wells
were blocked with assay diluent for 1 hr at room temperature. Standards and samples
were added to the wells at a total volume of 100 pl/well. TNF-a and IL-ip standards
provided by the kits ranged from 15.6-500 pg/mL after serial dilutions. Culture media
from primary cultures and plasma from isolated blood samples were added to the wells
at a volume of 100 pl/well. Tissue samples were homogenized in PBS with proteinase
inhibitors ( 1 : 1 0 0 0 ) and added to the wells at a concentration of 2 0 0 pg protein/well.
Assay diluent was added to reach the total well volume of 100 pi. Standards and
samples were incubated overnight at 4°C or at room temperature for 2 hr. After removal
of standards and samples, the wells were incubated with the detection antibody for 1 hr
at room temperature. Then the wells were incubated with the active enzyme AvidinHRP for 30 min at room temperature. The working substrate solution was then added to
the wells for 10-15 min at room temperature before addition of the stop solution ( 1 M
H3PO4) to end the reaction. The plate was read at 450nm using SpectraMax M5 plate
reader and SoftMax Pro software (Molecular Devices, Sunnyvale, CA).
2.5

L a n g en d o rff Perfusion System

Langendorff perfusion preparations were prepared according to the methods
previously described (Peng et al. 2005). After treatment, mice were given heparin (50
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USP units/mouse) before sacrifice. Hearts were retrieved and the ascending aorta was
cannulated and attached to the Langendorff perfusion system. Hearts were perfused with
bubbled (mixture of 95% O2 and 5% CO2) Krebs solution at a rate of 2 mL/min (-100
mmHg). Myocardial function was assessed by securing a 6-0 silk suture approximately
2mm from the apex of the LV which was also attached to a lightweight coupling rod.
The coupling rod was connected to a force-displacement transducer (model FT03, Grass
Instruments, West Warwick, RI) to record tension and heart rate. Tension was
maintained at 2 grams during recordings. The heart work was calculated by multiplying
the force (grams) by the heart rate (bpm). Maximal and minimal first derivatives of
force (+dF/dtmax and -dF/dtmjn) used to approximate the rate of contraction and
relaxation were analyzed by PowerLab Chart 4 program (AD Instruments, Colorado
Springs, CO).
2.6

H em odynam ic A nalysis

Hemodynamic measurements were performed as previously described (Feng et
al. 2001; Peng et al. 2003). Mice treated with LPS were given subcutaneous saline
injections (0.5 mL) every Zi hr for the 4 hr treatment time. Volume resuscitation was not
necessary in control mice. Mice were then anesthetized with a ketamine (50 mg/kg) and
xylazine (12.5 mg/kg) mixture for catheter placements. Body temperature was
monitored by a rectal temperature probe (TC-1000 Temperature Controller, CWE Inc.,
Ardmore, PA) and maintained between 36 and 37.5°C by heating pads and lamps on the
procedure bench. The right carotid artery was cannulated with a pressure-conductance
catheter (Model SPR-839, Size 1.4F, Millar Instruments, Houston, TX) to record mean
arterial pressure (MAP) in the right carotid artery. The catheter was then advanced
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retrogradly into the LV for recording of heart rate, LV ejection fraction (LVEF), CO,
derivatives of LV pressures (+dP/dtmax and -dP/dtm¡n), LV end systolic pressure
(LVESP), LV end diastolic pressure (LVEDP), LV end diastolic volume (LVEDV),
time constant of isovolumic relaxation (Tau), maximal power, and LV conductance.
Both pressure and conductance signals were fed to an analog-digital converter and
analyzed by PowerLab Chart 4 software (AD Instruments Inc., Colorado Springs, CO).
Catheter pressure baselines were recorded before and after each experiment. After LV
pressure measurements, occlusion of the inferior vena cava was performed by direct
pressure on the inferior vena cava in an open abdominal cavity to test volume dependent
pressure loading in the heart. Ten pi of isotonic saline (0.9% NaCl) bolus injections
were given in the jugular vein to obtain parallel conductance for the calculation of LV
volume.
2.7

M acrophage Isolation

Isolation Procedure
Peritoneal macrophages were isolated from mice 4 days after i.p. injection (1.5
mL/mouse) of 3% thioglycollate medium (Sigma-Aldrich, St. Louis, MO) to induce
peritonitis as previously described (Zhao et al. 2006). Briefly, a lavage (4 mL 3x) of the
peritoneum was performed with RPMI 1640 media (Invitrogen, Burlington, ON). The
cells were collected after centrifugation at 1000 g for 3 min and counted using a
hemocytometer. The cells were then plated at a concentration of 1.5x105 cells/well on
48 well Costar plates (Coming Inc., Coming, NY) and incubated for 2 hr at 37°C. Cells
were then washed 4x with PBS to remove any non-adherent, and thus non-macrophage,
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cells. Cells were incubated in RMPI 1640 media with 5% FBS overnight at 37°C in a
humidified chamber containing 5% CO2 .
Treatments
The control group contained RPMI 1640 media (Invitrogen, Burlington, ON)
with 5% FBS, which served as the media for each treatment group. The media was
supplemented with 2 mM Ca2+ to reflect physiological conditions, unless stated
otherwise. Annexin A5 treatment at 1 pg/mL was used (Biovision, CA). LPS treatment
had Salmonella typhosa (Sigma-Aldrich, St. Louis, MO) concentrations of 0.01, 0.1,
0.4, and 1 ng/mL. Cells treated with LPS+annexin A5 received combinations of A5 and
LPS concentrations used in the individual treatment groups. After the 4 hr treatment, the
culture medium and plate was collected and stored separately at -80°C.
2.8

Isolation o f N eonatal Cardiomyocytes

Isolation Procedure
Neonatal mouse cardiomyocyte cultures were prepared by methods previously
described (Song et al. 2000; Peng et al. 2003; Peng et al. 2005). Briefly, ventricles from
C57BL/6 WT mice bom within 24 h were minced in a nominally Ca2+ and Mg2+ free
Hanks balance solution. Cardiac myocytes were dispersed by 22.5 pg/mL liberase
blendzyme IV (Roche, Laval, QC) in D-Hanks solution at 37°C for 40 min. The isolated
cells were pre-plated for 90 min to remove adherent non-cardiomyocytes. Purity of
cardiomyocytes determined by flow cytometry using an a-actinin antibody was 98.7%
after 72 hours of cell culture (Hammoud et al. 2009). The cardiomyocytes were plated at
a density of 0.7xl0 6 cells/well in M199 medium containing 10% FCS in 24 well Costar
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plates (Coming Inc., Coming, NY) pre-coated with 1% gelatin. Cells were incubated at
37°C in a humidified chamber containing 5% CO2 . After culturing for 48 hr to allow
confluence, cardiomyocytes were treated.
Treatments
The control group contained M l99 with 10% FCS, which served as the media
for each treatment group. Annexin A5 treatment was 1 pg/mL (Biovision, Mountain
View, CA). LPS treatment contained Salmonella typhosa (Sigma-Aldrich, St. Louis,
MO) concentrations of 0.1, 0.2, and 1 pg/mL. Cells treated with LPS+A5 received
combinations of A5 and LPS concentrations used in the individual treatment groups.
After 4 hr of treatment the culture medium and plate was collected and stored separately
at -80°C.
2.9

Isolation o f A d u lt Cardiomyocytes

Isolation Procedure
Cardiomyocytes were isolated from the hearts of adult C57BL/6 WT mice as
previously described (Zhou et al. 2000; Burger et al. 2009). Mice were given heparin
(50 USP units/mouse) before sacrifice. Hearts were retrieved and the extended aorta was
cannulated and attached to the Langendorff perfusion system. The heart was perfused
with buffer (NaCl 113mM, KC14.7 mM, MgSO4-7H20 1.2 mM, NaH2P 0 4 0.6 mM,
NaHCC>3 12 mM, Glucose 5.5 mM, 2,3-butanedione monoxime 10 mM, taurine 30 mM)
containing 45 pg/mL of liberase blendzyme IV (Roche, Laval, QC) for 4 min to flush
away blood and extracellular Ca before perfusion with myocyte digestion buffer
(perfusion buffer pH 7.46, Ca2+ 12.5 pM, 45 pg/mL liberase blendzyme IV (Roche,
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Laval, QC)) for approximately 8-10 min. The heart was then removed from the cannula
and placed in a 60 mm dish containing the cell suspension. The heart was cut and teased
into several small pieces and transferred to a 15 mL tube containing myocyte-stopping
buffer (perfusion buffer pH 7.46, bovine calf serum 10%, Ca2+ 10 mM). The cells were
counted with a hemacytometer to check viability.
The cells were then re-suspended and exposed to a series of sedimentation and
resuspension steps in buffers containing increasing concentrations of Ca2+ (12.5 pM-1.0
mM) in a 5-step process allowing 4 min at each step. The cells were transferred to a 15
mL tube and resuspended in myocyte plating medium (minimum essential medium 0.9x,
bovine calf serum 5%, 2,3-butanedione monoxime 10 mM, penicillin 100 U/mL, Lglutamine 2 mM, Ca2+ 1.2 mM). The myocyte plating medium was equilibrated for 2-3
hr at 37°C in 2% CO2 incubator to temperature and pH balance to approximately 7.
Each heart routinely yields approximately lxlO 7 rod-shaped myocytes and the cells
were counted with a hemocytometer. The cell concentration was adjusted to 25,000 rod
shaped cells/mL and plated on laminin-coated 35 mm dishes at a density of 50 rod
shaped cells/mm .
Treatment
Isolated adult cardiomyocytes were incubated in equilibrated myocyte culture
medium (minimum essential medium lx, penicillin 100 U/mL, L-glutamine 2 mM, FBS
5%) for 6 hr at 37°C in a 2% CO2 incubator before treatment. The control group
contained myocyte culture medium, which served as the media for each treatment group.
The culture medium was equilibrated for 2-3 hr 37°C in a 2% CO2 prior to use to adjust
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temperature and pH balance to approximately 7. Annexin A5 treatment was 1 pg/mL
(Biovision, Mountain View, CA) and LPS treatment was 2.5 pg/mL of Salmonella
typhosa (Sigma-Aldrich, St. Louis, MO). After 4 hr of treatment, the culture medium
and plate were collected and stored separately at -80°C.
Adult cell RNA Isolation
Before freezing samples at -80°C, the cells were washed with PBS to remove
residual media. RNA isolation was performed using an RNeasy kit (Qiagen,
Mississauga, ON). Briefly, the duplicate dishes were combined to increase mRNA
concentration and cells were lysed in RLT buffer and mixed with 1 volume of 70%
ethanol. The solution was transferred to RNeasy columns to capture RNA. The columns
were washed with kit buffers and RNA was collected in RNase free DEPC-H2O. RNA
concentration was quantified by measuring the absorbance at 260/280 nm using a
RNA/DNA calculator (Pharmacia Biotech, Gene Quant II, Baie d’Urfe, QC). cDNA
synthesis was performed as previously described.
2.10

Co-Im m unoprecipitation

Co-immunoprecipitation of TLR4 and annexin A5 was performed using the
Dynabead Protein G Immunprecipitation kits (Invitrogen, Burlington, ON) as per
manufacturer instructions, with minor revisions. Briefly, the magnetic dynabeads were
suspended in an antibody-binding buffer with 20 pg of TLR4 antibody (Santa Cruz,
Santa Cruz, CA) for 1 hr at room temperature. To immunoprecipitate annexin A5 from
the sample, heart tissues were homogenized in NP40 cell lysis buffer and sonicated for
10 seconds at 2 output watts. Protein concentrations were measured using a Lowry
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protein assay (Bio-Rad, Mississauga, ON) using bovine serum albumin (BSA) as the
standard. Concentrations were measured to allow for equal loading of 1 mg protein per
tube. Human recombinant annexin A5 (0.5 jig) (Biovision, Mountain View, CA) was
added to the tissue samples and incubated with the TLR4-coated beads for 2 hr at room
temperature. The samples were eluted from the dynabeads by boiling for 8 min in
elution buffer and reducing protein-loading dye. The samples were then equally loaded
on a 10% polyacrylamide gel and a western blot was performed for annexin A5
detection (anti-rabbit, 1:2000, Biovision, Mountain View, CA). The membrane was
stripped using stripping buffer and rotating for 20 min at 50°C, and then reprobed for
TLR4 detection (anti-rabbit, 1:500, Santa Cruz, Santa Cruz, CA) as a control.
2.11

Statistical A nalysis

All results are expressed as mean ± SEM. Two-way analysis of variance
(ANOVA) followed by unpaired Student’s t test with Bonferroni corrections was
performed to detect differences between treatment groups using Prism 4.0 (GraphPad
Software, La Jolla, CA). Statistical significance was assigned when a P value was less
than 0.05.
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Chapter 3 - RESULTS
3.1

A nnexin A 5 treatm ent abrogates LP S-induced m yo cardialp38 and E R K

M A P K phosphorylation

The LPS-induced TLR4 signalling pathway is regulated by MAPKs and can
result in NF-kB activation within 30 min of LPS exposure (Baumgarten et al. 2001).
Therefore, to determine if annexin A5 affects the TLR4 signalling pathway, myocardial
p38 and ERK MAPK phosphorylation (P-p38, P-ERK) was measured after 30 min
treatment of LPS (4 mg/kg i.p.). Phosphorylation MAPK activation was measured as a
ratio of protein phosphorylation levels compared to total protein levels by western blot
analysis. LPS treatment significantly increased phosphorylation of p38 (P<0.05, Figure
6A

and 6 B) and ERK (P<0.05, Figures 7A and 7B). The responses were inhibited with

annexin A5 treatment (5 pg/kg i.v.) to similar levels as control (P<0.05, Figure 6 and 7).
3.2

A nnexin A S treatm ent abrogates L P S-induced m yocardial TLR4 and NO X2

m RNA expression

To determine if annexin A5 affected LPS-induced gene transcription through the
MAPK-dependent pathway, we measured the mRNA expression of TLR4 and NOX2,
two proteins shown to be essential for cardiomyocyte LPS-induced gene expression
(Baumgarten et al. 2001; Peng et al. 2005). mRNA expression was measured in isolated
LVs after 4 hr of LPS (4 mg/kg i.p.) treatment using real-time RT-PCR with 28S mRNA
expression as a loading control. LPS increased myocardial TLR4 and NOX2 mRNA
expression by 2-fold and 3-fold respectively (P<0.05) and the response was inhibited
with annexin A5 treatment (5 pg/kg i.v.)(P<0.01, Figures

8

and 9).
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P-p38

43 kDa

Figure 6. Annexin A5 abrogates LPS-induced myocardial p38 MAPK phosphorylation.
Mice were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.)
for 30 min. Phosphorylation of p38 was analyzed by western blot analysis and expressed
as a ratio of P-p38/Total-p38 band intensity. A: Representative western blot. B: Graph
representing densitometry of Western blot analysis. N numbers are given in each
column above. * P<0.05 vs. Control and A5, f P<0.05 vs. LPS.
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Figure 7. Annexin A5 abrogates LPS-induced myocardial ERK1/2 MAPK
phosphorylation. Mice were treated with LPS (4 mg/kg i.p.) with and without annexin
A5 (5 pg/kg i.v.) for 30 min. Phosphorylation of ERK was analyzed by western blot
analysis and expressed as a ratio of P-ERK/Total-ERK band intensity. A: Representative
western blot. B: Graph representing densitometry of Western blot analysis. N numbers
are given in each column above. * P<0.05 vs. Control and A5, f P<0.05 vs. LPS.
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Figure 8. Annexin A5 abrogates LPS-induced myocardial TLR4 mRNA expression.
Mice were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.)
for 4 hr. TLR4 mRNA levels were measured as a ratio of 28S using real time RT-PCR
analysis. N numbers are given in each column above. * P<0.05 vs. Control and A5, f
¿*<0.01 vs. LPS.
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Figure 9. Annexin A5 abrogates LPS-induced myocardial NOX2 mRNA expression.
Mice were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.)
for 4 hr. NOX2 mRNA levels were measured as a ratio of 28S using real time RT-PCR
analysis. N numbers are given in each column above. * P<0.05 vs. Control and A5, f
PO .Ol vs. LPS.
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3.3

A nnexin AS treatm ent attenuates m yocardial TN F -a and IL -lfi expression

Our lab has shown previously that LPS-induced myocardial cytokine expression
depends on the TLR4 signalling pathway that includes NOX2, p38, and ERK (Peng et
al. 2003; Peng et al. 2005). Real time RT-PCR and ELISA analyses were used to
measure cytokine mRNA and protein expression, respectively. After 4 hr treatment of
LPS (4 mg/kg i.p.), LV myocardial TNF-a mRNA levels increased approximately 10
fold, which was associated with a 2-fold increase in protein levels (P<0.05, Figure 10A
and 10B). Conversely, LV myocardial IL-1|3 mRNA levels increased after LPS
treatment (P<0.05) but protein levels did not change (Figure 11A and 1IB). Annexin
A5 treatment (5 pg/kg i.v.) inhibited TNF-a and IL-ip mRNA expression but did not
fully decrease TNF-a protein levels to control values (P<0.05, Figure 10 and 11).
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Figure 10. Annexin A5 attenuates LPS-induced myocardial TNF-a expression. Mice
were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.) for 4hr.
A: TNF-a mRNA levels were measured as a ratio of 28S using real time RT-PCR
analysis. B: TNF-a protein levels measured by ELISA analysis. N numbers are given in
each column above. * P<0.05 vs. Control and A5, f P<0.05 vs. LPS.
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Figure 11. Annexin A5 abrogates LPS-induced myocardial IL-lp mRNA expression.
Mice were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.)
for 4hr. A: IL-ip and mRNA levels were measured as a ratio of 28S using real time RTPCR analysis. B: IL-ip protein levels measured by ELISA analysis. N numbers are
given in each column above. * P<0.05 vs. Control and A5, f P<0.05 vs. LPS.
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3.4

A nnexin A 5 treatm ent attenuates cardiac dysfunction during endotoxem ia

Increased levels of TNF-a and IL-1J3 have been shown to directly inhibit cardiac
function during sepsis (Kumar et al. 1996; Cain et al. 1999; Grandel et al. 2000).
Previously, our lab had demonstrated LPS-induced cardiac dysfunction after 4 hr using a
Langendorff system (Peng et al. 2005). Contractile force was measured in the
Langendorff system using a force-displacement transducer attached to the apex of the
LV by a silk suture. Cardiac function was measured by changes in the force of
contraction and relaxation (+dF/dtmax and -dF/dtmjn, respectively) and heart work. After
4 hr of LPS treatment (4 mg/kg i.p.), ±cLF/dtmax/min and heart work were decreased when
compared to control mice (P<0.01, Figure 12). Annexin A5 treatment (5 pg/kg i.v.)
prevented LPS-induced cardiac dysfunction (P<0.01, Figure 12). There was no change
in heart rate between any of the groups.
3.5

A nnexin A 5 treatm ent attenuates hem odynam ic dysfunction during

endotoxem ia

Cardiovascular hemodynamics were measured to determine the extent of
annexin A5 protection on cardiac function in vivo. A Millar pressure-conductance
catheter was used to measure arterial pressure and changes in LV pressure and volume.
Hemodynamic parameters obtained include MAP, heart rate, LVEF, CO, +dP/dtmax and
-dP/dtmin, LVESP, LVEDP, LVEDV, Tau and maximal power (see Table 1 and Figure
13). Following LPS treatment (4 mg/kg i.p.), MAP, +dP/dtmax and -dP/dtmin, LVESP,
LVEDP and maximal power were significantly decreased (P<0.01) while Tau was
significantly higher (P<0.01). Treatment with annexin A5 (5 pg/kg i.v.) resulted in
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significantly higher MAP and lower Tau when compared to endotoxemic mice (PO.05,
Table 1). Importantly, +dP/dtmax and -dP/dtmin function was significantly higher by
approximately 35% and 33% respectively in LPS with annexin A5 treatment compared
to the LPS group (P<0.05, Figure 13).
3.6

A nnexin A 5 treatm ent attenuates L P S -in du cedplasm a TNF-a an d IL -lfi levels

Systemic inflammation with excessive cytokine production is characteristic of
sepsis. Blood was isolated from heart puncture and the plasma was separated by
centrifugation to measure plasma cytokine levels by ELISA analysis. TNF-a and IL-1 (3
levels were significantly higher in response to 4 hr LPS (4mg/kg i.p.) treatment
(P<0.01), with TNF-a levels almost 5 times greater than IL-1 P levels (Figure 14A and
14B). In contrast to myocardial cytokine expression where annexin A5 eradicated TNF
a and IL-ip expression after 4 hr of LPS (Figure 10 and 11), annexin A5 treatment (5
pg/kg i.v.) only attenuated TNF-a and IL-1 [3 plasma levels by 34% and 51%
respectively (P<0.05, Figure 14A and 14B). Although IL-1 P levels with LPS and
annexin A5 treatment were not significantly different from control values, they show a
strong trend towards higher IL-1 P levels (P=0.06).

45

B

D

Figure 12. Annexin A5 attenuates cardiac dysfunction during endotoxemia. Hearts were
isolated and perfused in a Langendorff system after mice were treated with LPS (4
mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.) for 4hr. A: Maximal and B:
minimal first derivatives of force (+dF/dtmax and -dF/dtmin) were measured to reflect the
rate of contraction and relaxation. D: Heart work was calculated as the product of force
(gram) and C: heart rate (bpm). Data was analyzed by PowerLab Chart 4 program. N
numbers are given in each column above. * P<0.01 vs. Control and A5, f PO.Ol vs.
LPS.
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Figure 13. Annexin A5 attenuates hemodynamic dysfunction during endotoxemia. Mice
were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.) for 4
hr. Mice were anesthetized and measurements of LV pressures were obtained using a
Millar pressure-conductance catheter. N numbers are given in each column above. *
P<0.05 vs. Control and A5, f P<0.05 vs. LPS.
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Table 1: In vivo hemodynamic measurements in mice with endotoxemia

Parameters

Control

A5

LPS

LPS+A5

n

10

11

9

11

Heart rate, beats/min

412±23

395±9

464±19

486±19

MAP, mmHg

86±3

83±5

49±3 **

59±4 ** f

LVEF, %

63±6

67±7

50±4

54±7

CO, pL/min

5188±834

3698±558

3153±786

4386±928

LVESP, mmHg

102±5

95±8

66±5 **

72±6 **

LVEDP, mmHg

6.9±0.9

8.3±2.1

3.6±0.1 **

4.5±0.5

LVEDV, pL

20±4

14±3

13±4

17±4

Tau, ms

7.9±0.3

8.1±0.5

10.2±0.4 **

8.6±0.6 f

Maximal Power, mWatts

6.1±1.1

4.4±0.8

2.0±0.5 **

3.7±0.9

Data are mean ± SEM and analyzed by two-way ANOVA followed by unpaired
Student’s t-test with Bonferroni corrections. ** P<0.01 vs. control, f P<0.05 vs. LPS.
MAP, mean artery pressure; LV ejection fraction (LVEF); CO, cardiac output; LVESP,
LV end systolic pressure; LVEDP, LV end diastolic pressure; LVEDV, LV end diastolic
volume; Tau, time constant of isovolumic relaxation.
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B

Figure 14. Annexin A5 attenuates LPS-induced plasma TNF-a and IL-ip levels. Mice
were treated with LPS (4 mg/kg i.p.) with and without annexin A5 (5 pg/kg i.v.) for 4
hr. The blood was isolated from heart puncture and the plasma was separated by
centrifugation for 10 min at 5,000 rpm. A: TNF-a and B: IL-ip levels were determined
by ELISA analysis. N numbers are given in each column above. * PO.Ol vs. Control
and A5, t P<0.05 vs. LPS.
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3 .7

A nnexin A S does not affect L P S-induced TNF-a production in macrophages

Macrophages are an abundant source of TNF-a in the body (reviewed by
Meldrum 1998). Since annexin A5 had an impact on TNF-a plasma levels (Figure 14),
we isolated and treated macrophages to determine if annexin A5 was inhibiting TNF-a
production at the cellular level. Macrophages were isolated from the peritoneum after
induction of peritonitis and plated on 48 well plates at 1.5x10s cells/well. Treatment
with 1 pg/mL of annexin A5 did not inhibit LPS-induced TNF-a release into the media
after 4hr as measured by ELISA analysis (Figure 15). Surprisingly, annexin A5
treatment alone induced significant levels of TNF-a protein. This response was
independent of Ca2+ concentration. We observed that medium supplemented with 2 mM
Ca2+ produced similar amounts of TNF-a after exposure to annexin A5 as Ca2+-free
medium (Figure 15). Macrophages did not readily produce IL-ip so it could not be
observed by ELISA analysis.
3.8

E ffects o f annexin A S on neonatal and adult cardiom yocyte TN F-a production

Since annexin A5 treatment during endotoxemia decreases myocardial cytokine
levels, we isolated and treated neonatal and adult cardiomyocytes to see if annexin A5
could interact directly with the myocardium. Neonatal cardiomyocytes were isolated in
liberase-IV containing D-Hanks solution and treated after 48 hr of cell culture to allow
confluence. Conversely, adult cardiomyocytes were treated after 6 hr of culture.
Neonatal cardiomyocytes produce substantial amounts of TNF-a in response to
LPS (Peng et al. 2003) but do not produce detectable levels of IL-ip protein in the
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supernatant (Westphal et al. 2007). We found that annexin A5 treatment of 1 pg/mL did
not affect TNF-a production and release into the supernatant after 4 hr LPS treatment of
0.1, 0.2, and 1 pg/mL, as measured by ELISA analysis (Figure 16).
In contrast, adult cardiomyocytes had decreased TNF-a and IL-ip mRNA
expression levels after 4 hr LPS (2.5 pg/mL) and annexin A5 (1 pg/mL) treatment, as
determined by real-time RT-PCR (P<0.05, Figure 17A and 17B). Expression of TNF-a
and IL-ip proteins in the media was not detectable because of the low plating density
(50 myocytes/mm ).
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Figure 15. Annexin A5 does not affect LPS-induced TNF-a production in isolated
macrophages. Peritoneal macrophages were isolated and plated on 48 well Costar plates
at a concentration of 1.5x105 cells/well. Cells were treated for 4 hr one day after
isolation and TNF-a levels were measured by ELISA analysis of cell media. The control
group contained RPMI 1640 media with 5% FBS, which served as the media for each
treatment group. LPS concentrations used were 0.01, 0.1, 0.4, 1 ng/mL, and annexin A5
concentration used was 1 pg/mL. The Ca2+ concentraion of the media was 2 mM unless
otherwise noted. N numbers are given in each column above. * PO.01 vs. Control,
LPS-0.01 and LPS-0.1.

Figure 16. Annexin A5 does not affect LPS-induced TNF-a production in neonatal
cardiomyocytes. Neonatal cardiomyocytes were plated on 24 well Costar plates at a
concentration of 0.7xl0 6 cells/well and treated 2 days after isolation. The control group
contained M l99 media with 10% FCS, which served as the media for each treatment
group. Cells were treated for 4 hr with LPS concentrations of 0.1, 0.2, and 1 pg/mL and
with an annexin A5 concentration of 1 pg/mL. TNF-a protein levels were measured by
ELISA analysis of cell media. N numbers are given in each column above. * P<0.01 vs.
Control and A5, f -PO.Ol vs. LPS-0.1.
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A

Figure 17. Annexin A5 abrogates LPS-induced TNF-a and IL-ip mRNA expression in
adult cardiomyocytes. Adult cardiomyocytes were plated on 35mm dishes. Culture
conditions and adult cell viability required cell treatment 6 hr after isolation. Cells were
treated with LPS 2.5 pg/mL and annexin A5 1 pg/mL for 4 hr, and A: TNF-a and B: ILlp mRNA levels were determined by real time RT-PCR analysis with 28S as a control.
N numbers are given in each column above. * P<0.01 vs. Control and A5, t F<0.05 vs.
LPS.
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3.9

A nnexin A 5 binds to TLR4

It has been shown previously that annexin A5 can interact with and inhibit cell
receptor function by binding to leucine-rich repeats through a conserved NH2-terminal
sequence (Markoff et al. 2007). Since mouse TLR4 has 19 separate leucine-rich repeats,
we performed a co-immunoprecipitation assay to identify potential interaction between
annexin A5 and TLR4 to help explain annexin A5’s ability to inhibit cytokine
production. Magnetic dynabeads were coated with anti-TLR4 antibody (Santa Cruz,
Santa Cruz, CA) to pull down TLR4 and blot for annexin A5. Annexin A5 human
recombinant was used as a positive control and Figure 18 qualitatively shows an
annexin A5 specific band in the control and LPS samples, denoting an interaction
between TLR4 and annexin A5. The membrane was stripped and reprobed for TLR4 as
a loading control.
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Figure 18. Annexin A5 interacts with TLR4 in myocardial tissue as determined by coimmunoprecipitation analysis. Myocardial tissue was homogenized and incubated with
0.5 pg of annexin A5. TLR4 protein was pulled down using magnetic beads coated with
anti-TLR4 antibody. This was followed by a western blot analysis for annexin A5. The
membrane was stripped and reprobed for TLR4. Lane 1, a control IgG with no sample.
Lane 2, a control myocardial sample from mice treated with saline. Lane 3, myocardial
sample from LPS-treated mice (4 mg/kg i.p. for 4 hours). Lane 4, recombinant annexin
A5 positive control. The blot shown is a representative from 4 experiments.
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Chapter 4 - DISCUSSION
The protective effect of armexin A5 on heart function during sepsis was
examined in mice with endotoxemia. It was found that administration of annexin A5 at
the same time as LPS decreased myocardial TLR4 signalling through p38 and ERK
pathways (Figure 6 and 7), leading to decreased levels of TNF-a and IL-ip in the heart
(Figure 10 and 11). The lower LPS-induced myocardial TNF-a and IL-ip levels after
annexin A5 treatment was reflected in the plasma cytokine levels (Figure 14) and
improved cardiac function during endotoxemia as measured using the Langendorff
perfusion system (Figure 12) and the Millar pressure-conductance catheter system
(Figure 13). Treatment of isolated adult mouse cardiomyocytes demonstrated a
cardiomyocyte-specific effect of annexin A5 in inhibiting LPS-induced TNF-a and ILip mRNA expression (Figure 17). Co-immunoprecipitation revealed annexin A5’s
ability to interact with TLR4 (Figure 18). These results suggest that annexin A5
provides a protective role in the heart during endotoxemia. The effects of annexin A5
may be due to annexin A5’s interaction with cell-surface receptor TLR4 and inhibition
of inflammatory signalling that leads to cardiac dysfunction (Figure 4).
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4.1

Findings

The p38 and ERK MAPKs are intimately involved in the TLR4-signalling
pathway after LPS stimulation (reviewed by Guha and Mackman 2001). TLR4
activation can lead to myocardial NF-kB nuclear translocation within 30 min of LPS
exposure in vivo (Baumgarten et al. 2001) and result in gene expression that can last for
hours. In this study we found that annexin A5 treatment abrogated p38 and ERK
phosphorylation 30 min after LPS treatment (Figure 6 and 7). The lower p38 and ERK
phosphorylation with annexin A5 treatment was reflected in lower mRNA transcription
of TLR4 and NOX2 after 4 hr (Figure 8 and 9), both components that are essential in
cardiomyocyte’s response to LPS (Peng et al. 2005; Boyd et al. 2006).
It has been demonstrated that cardiomyocytes are the predominant source of
inflammatory cytokines in the heart (Kapadia et al. 1995; Peng et al. 2003). In this study
we established that annexin A5 treatment resulted in lower myocardial TNF-a mRNA
and protein and IL-lp mRNA levels 4 hr after LPS treatment (Figure 10 and 11). This is
consistent with a previous study in our lab that showed inhibition of p38 and ERK
blocked myocardial TNF-a expression (Peng et al. 2005).
Biologically active TNF-a protein is produced in large amounts and appears as
early as 1 hr after LPS exposure (Kapadia et al. 1995) while IL-1(3 is less prominent and
is produced several hours later as a result of TNF-a induction (reviewed by Dinarello
1996; Cain et al. 1999). This could be one explanation of why IL-ip protein levels did
not increase in the myocardium similar to TNF-a 4hr after LPS treatment. In addition,
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the cytokines produced by the myocardium undergo post-transcriptional modification
and are readily released into the circulation or surrounding tissue, an explanation likely
responsible for the difference in fold change between TNF-a mRNA and protein
production.
TNF-a and IL-ip have been shown to act synergistically to induce a shock-like
state in animals (Okusawa et al. 1988) and inhibit myocyte contractility (Cain et al.
1999). Since cardiac depression is associated with increased TNF-a levels (Grandel et
al. 2000), this thesis demonstrated that lower TNF-a levels after annexin A5 treatment
correlated with better cardiac function during endotoxemia (Figure 12 and 13). We
observed full protection of cardiac function using the ex vivo Langendorff perfusion
model (Figure 12). The Langendorff model provided a constant flow rate that allowed
the heart to function independent of fluid loss, preload limitations, and neurohumoral
influences to achieve normal cardiac function that was not present in the whole animal
hemodynamics analysis. In the hemodynamic analyses, annexin A5 attenuated cardiac
dysfunction by approximately 35% and 33% in +dP/dtmax and -dP/dtmin respectively,
which is similar to the 34% lower TNF-a plasma levels in the presence of annexin A5
(Figure 14A). IL-ip plasma levels were lowered by approximately 51% with annexin
A5 treatment (Figure 14B), but circulating IL-ip levels were almost 5 times lower than
TNF-a and would likely have a more modest role in cardiac dysfunction compared to
TNF-a.
The lower MAP observed in the LPS treated mice reflects a decrease in SVR.
Low blood pressure can activate the baroreceptor reflex and initiate a compensatory
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mechanism to increase heart rate and maintain CO. There was a strong trend towards
higher heart rates in LPS and LPS+annexin A5 treated mice (Table 1). Surprisingly,
there was a trend toward a lower heart rate in the annexin A5-alone treated mice that did
not reach significance (Table 1). Currently there is no evidence of annexin A5’s
involvement in autonomic regulation or adrenergic signalling to affect heart rate.
Conversely, annexin A6 is involved in Ca2+ regulation in the heart because functional
studies reveal that knockout of annexin A6 led to an increase in Ca2+ cycling efficiency
from the sarcoplasm (Song et al. 2002). Ca2+ cycling efficiency is increased when heart
rate is increased to boost contractility of the cardiomyocytes. However, it was observed
that the reduction or over-expression of annexin A6 had no effect on heart rate
(Gunteski-Hamblin et al. 1996; Song et al. 2002).
It has also been shown that annexin A6 is reduced in the failing heart which
increases contraction-relaxation dynamics of the heart to compensate for increased
cardiovascular demand (reviewed by Kaetzel and Dedman 2004). In contrast, annexin
A5 is upregulated in the failing heart (Matteo and Moravec 2000) and therefore
probably has a different role, if any, in Ca2+ cycling in the heart compared to annexin
A6.
No research has been done to investigate annexin A5’s interaction with the
central nervous system or autonomic regulation of heart function. Given the evidence
that annexin A5 did not affect heart rate in the Langendorff perfusion system (Figure
12), annexin A5’s influence on heart rate could be a result of experimental procedures
and sample sizes, or it may have an indirect effect not yet investigated.
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This thesis has demonstrated that annexin A5 treatment prior to endotoxemia
abrogates myocardial cytokine production and lessens cardiac dysfunction. In order to
further elucidate the mechanism of annexin A5 function, we isolated peritoneal
macrophages and neonatal and adult cardiomyocytes to determine if annexin A5 was
interacting with the myocardium at the cellular level. In our study, we did not see
annexin A5 inhibit the release of TNF-a from the macrophage or neonatal cell’s into the
supernatant (Figure 15 and 16). In contrast, we saw that annexin A5 treatment alone
significantly increased TNF-a production in isolated macrophages (Figure 15). This
response was independent of the Ca2+ concentration used. The Ca2+ concentration
needed for half-maximal binding of annexin A5 to negatively charged phospholipids is
approximately 10 -100 pM (reviewed by Gerke and Moss 1997) and we observed that
medium with or without Ca2+ produced similar amounts of TNF-a after exposure to
annexin A5. Therefore, annexin A5 was able to interact with isolated macrophages in a
Ca -independent manner. This is consistent with previous studies that demonstrate
potential immunomodulatory effects of annexin A2 and A5 on macrophages (Munoz et
al. 2007; Swisher et al. 2007; Swisher et al. 2009). Annexin-induced activation of
inflammatory mediators in macrophages has been proposed to ‘prime’ macrophages for
efficient microbial clearance and to increase the immunogenicity of apoptotic cells
(Munoz et al. 2007; Swisher et al. 2007). Interestingly, we did not see any inflammatory
response in the plasma (Figure 14) or myocardial tissue (Figure 10 and 11) after annexin
A5 treatment alone, suggesting that macrophages may only respond to annexins in
situations of stress, injury, or invasion.
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While neonatal cardiomyocytes produce substantial amounts of TNF-a in
response to LPS treatment (Figure 16), IL-ip was not detectable in the supernatant. This
is consistent with a recent study that found rat neonatal cardiomyocytes produce IL-ip
mRNA but did not release mature protein 5 hr after LPS treatment (Westphal et al.
2007) because a significant amount of pro-EL-l(3 remained in the cell (Mosley et al.
1987). This is also consistent with our results of IL-1 p production in the myocardium
where we did not see an increase in myocardial IL-1P protein expression after 4 hr LPS
treatment (Figure 11). Similarly, macrophages are unable to process and release IL-ip
solely by TLR ligands (Netea et al. 2009), which is the primary mode of activation by
LPS.
In contrast to annexin A5’s influence on macrophage and neonatal
cardiomyocyte TNF-a expression, annexin A5 inhibited TNF-a and IL-1 P mRNA
expression after LPS treatment in adult cardiomyocytes (Figure 17). Moreover, a coimmunoprecipitation of annexin A5 and TLR4 displayed a possible interaction that
could be attributed to annexin A5’s ability to control myocardial inflammation through
inhibition of TLR4 signalling (Figure 18). It is likely that annexin A5’s conserved NH2terminal sequence interacts with one of TLR4’s 19 leucine-rich repeats (Markoff et al.
2007). Annexin A5 has also been shown to interact with and regulate surface receptor
expression (Ravassa et al. 2005). It’s ability to interact with various cell surface
receptors may remove it from the circulation and could help to explain its lasting impact
hours after treatment given its short plasma half-life of approximately 15 min (Teoh et
al. 2007).

62

While we were able to measure cytokine mRNA levels in isolated adult
cardiomyocytes, our inability to obtain TNF-a and IL-ip protein measurements is
reflective of the difficulty to work with adult cardiomyocytes. Adult cardiomyocytes are
less viable than their neonatal counter parts and therefore must be plated at a much
lower density and treated on the same day as isolation. Given these culture conditions,
mRNA measurements were the only achievable measurement for cytokine activity in
adult cells. Also, under certain circumstances, adult cardiomyocytes may respond
differently than their neonatal counterparts. For example, adult cardiomyocytes have
been shown to have longer action potential durations than neonates (Nuss and Marban
1994) and they also undergo apoptosis at doses of LPS that do not initiate similar
apoptotic responses in neonatal cells (Hickson-Bick et al. 2006).
Furthermore, it has been shown that neonatal cardiomyocytes express low levels
of CD 14 and LBP and are activated by LPS in a CD-14-independent manner (Cowan et
al. 2000). Conversely, adult cardiomyocytes are hyposensitive to LPS exposure when
CD-14 function is inhibited (Comstock et al. 1998). The differing expression and
utilization of TLR4 binding components in adults and neonates may affect annexin A5’s
ability to bind to TLR4 via leucine-rich repeats and inhibit TLR4 signalling. Neonatal
cardiomyocytes also show more similarity with macrophages in NF-kB pathway
activation in response to LPS than with adult cardiomyocytes (Liu et al. 2001; Cuenca et
al. 2007). This may shed light on the disparity of annexin A5 impact on macrophage and
neonatal cells compared with adult cardiomyocyte TNF-a production.
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Data from this thesis suggest that annexin A5 may interact with TLR4 to inhibit
myocardial cytokine production, but it is possible that annexin A5 may also be
interacting with other cell membrane receptors. In 2006, Tavener demonstrated through
knockout studies that both TNF-a receptors 1 and 2 (TNFR1/2) are necessary for
myocyte dysfunction after LPS treatment (Tavener and Kubes 2006). In addition,
Tavener also reported that leukocyte TLR4 expression and not cardiomyocyte TLR4
expression was responsible for contractile dysfunction after LPS treatment (Tavener et
al. 2004). However, while leukocytes are vital for the inflammatory response to
infection, there is currently no direct evidence for leukocyte or neutrophil infiltration
being responsible for cardiac dysfunction (Raeburn et al. 2002). The evidence that
annexin A5 is able to inhibit pro-inflammatory cytokine mRNA expression in adult
cardiomyocytes (Figure 17) is consistent with our observations that annexin A5 protects
the heart from LPS-induced cardiac dysfunction (Figure 12 and 13), but not from
systemic inflammation (Figure 14). So while the impact of other cell receptors cannot be
mled out and must be further investigated, we believe that cardiomyocyte TLR4 is the
prominent cell receptor responsible for mediating sepsis-associated cardiac dysfunction
through which annexin A5 principally acts (Baumgarten et al. 2001; Baumgarten et al.
2006; Boyd et al. 2006).
This thesis gives evidence for annexin A5 to be protective in endotoxemiainduced cardiac dysfunction by inhibiting myocardial cytokine production through
direct interaction with TLR4.

64

4.2

L im itations

Mouse Model o f Human Disease Conditions
The use of mice to study human disease is necessary in the evaluation of
potential therapeutics for both ethical and practical reasons. Animal models allow for
control of experimental conditions and collection of tissue samples that are otherwise
not possible in humans. Mice also provide an economic benefit with short gestation and
maturity periods that allow increased sample sizes to make the study of adult related
diseases much more accessible.
This thesis utilized LPS to simulate human sepsis. LPS, a gram-negative
endotoxin, is effective in inducing a sepsis-like state in animal models (Natanson et al.
1986) but it is not exhaustive in simulating all sepsis-associated infections. In a study
cataloging sepsis cases from 1979 through 2000, it was found that only 37.6% of the
cases were a result of gram-negative bacteria infection, while the rest was made up of
gram-positive bacteria, polymicrobial, and fungi infections (Martin et al. 2003).
Moreover, in a recent study, it was determined that 67% of infections originated in the
lungs while only 22% were in the abdomen (Vincent et al. 2006). Nonetheless, the
model of LPS induced endotoxemia through intraperitoneal injection continues to be
one of the most prominently accepted sepsis-models as it is easily reproduced and
provides an appropriate model for studying many manifestations of sepsis.
Dosing
Our lab has shown previously that an LPS dose of 4 mg/kg i.p. is appropriate to
induce cardiac dysfunction after several hours in mice (Peng et al. 2005; Peng et al.

2008; Peng et al. 2009). In contrast, the effect of annexin A5 treatment during
endotoxemia has not been examined. An annexin A5 dose of 5 pg/kg i.v. was used
because it provided cardiac protection during endotoxemia and there was no previous
evidence of a more optimal dose of annexin A5 for sepsis-associated organ dysfunction.
Previous studies investigating the role of diannexin, a recombinant annexin A5
homodimer, in liver ischemia/reperfusion injury used doses ranging from 100-1000
pg/kg (Shen et al. 2007; Teoh et al. 2007). This dose is much greater than the dose of
5pg/kg used in this thesis because ischemia/reperfusion injury is a greater risk to tissue
and organ damage.
However, we did not investigate the efficacy of annexin A5 over a range of
doses, thus limiting our knowledge of its potential clinical usefulness and impact on
other organ systems during sepsis.
Timing
Although the total number of sepsis-associated deaths continue to increase, the
total in-hospital mortality rate fell approximately 10% from the early 1980’s to the late
1990’s (Martin et al. 2003). Improved characterization and understanding of sepsis has
no doubt had a beneficial effect on patient prognosis, but the major caveat in sepsis
therapy continues to be the time at which identification of sepsis can occur. Early
identification and therapy directly reduces mortality rates (Rivers et al. 2001).
In this thesis, annexin A5 was administered at the same time as LPS and may act
as a preventative treatment rather than a restorative treatment. However, annexin A5 has
been shown to inhibit inflammatory mechanisms and decrease tissue damage up to 1 hr
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after ischemia/reperfusion liver injury (Teoh et al. 2007). Since sepsis is a selfperpetuating disease, it is encouraging that annexin A5 may be able to inhibit the
progression of inflammation.
In addition, it would be beneficial to have a more comprehensive time course
detailing the inflammatory response in the presence of annexin A5. For example, MAPK
phosphorylation was analyzed after 30 min to demonstrate its activity after LPS
treatment and its involvement in the TLR4-signalling pathway (Figure 6 and 7).
However, since cytokine production and cardiac function were assessed after 4 hr, we
cannot conclude that there is a direct correlation between MAPK phosphorylation and
cytokine production and cardiac function. Therefore, we are limited to a snapshot of the
model we have established.
4.3

Suggestions f o r F uture Research

Annexin A5 was originally identified as an anti-coagulant with antithrombotic
activity (Reutelingsperger et al. 1985). More recently it has been shown to be a potent
anticoagulant through inhibition of platelet adhesion, prothrombinase complex
formation, and fibrin deposition, thus maintaining microvascular circulation (van
Heerde et al. 1994; London et al. 1996; Kuypers et al. 2007; Shen et al. 2007; Teoh et al.
2007). Interestingly, the anticoagulant drotrecogin alfa (activated), a recombinant human
activated protein C, has displayed improved survival and respiratory and cardiovascular
function in sepsis in phase HI clinical trials (Ely et al. 2003; Kalil et al. 2004). Activated
protein C has also been demonstrated to have anti-inflammatory properties through
inhibition of NF-kB activation, cytokine production, and leukocyte cell rolling and
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adhesion (Grey et al. 1994; Joyce and Grinnell 2002; Favory et al. 2006; Lehmann et al.
2008). Therefore, it would be beneficial to investigate the role of annexin A5 in the
microvascular circulation and coagulatory systems during sepsis.
It is also possible that annexin A5 may improve cardiac function during
endotoxemia by additional mechanisms not explored in this thesis. Despite the fact that
apoptosis is very low in the myocardium and believed not to be responsible for cardiac
dysfunction in endotoxemic mice, LPS and TNF-a induce caspase activation and
apoptotic pathways in the heart (reviewed by Carlson et al. 2005; Crouser 2005).
Moreover, inhibition of caspase activation or overexpression of Bcl-2 attenuated
myocardial dysfunction in mice (Fauvel et al. 2001; Lancel et al. 2005). While there is
currently no evidence for annexin A5 to have anti-apoptotic mechanisms beyond the
inhibition of phagocytosis at the cell membrane level, it has been shown that uptake of
annexin A5 in rat cardiomyocytes during endotoxemia could be caspase-dependent
(Petillot et al. 2007). Therefore, further study needs to be done in order to determine if
annexin A5 internalization is related to or simply a result of caspase activation and if it
has any affect on caspase activity and apoptosis.
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4.4

Conclusion

In conclusion, the results of this thesis demonstrate that annexin A5 treatment at
the onset of endotoxemia attenuates TNF-a and IL-ip production and prevents cardiac
dysfunction. It was found that annexin A5 might interact with TLR4 to inhibit an
excessive LPS-induced inflammatory response. However, annexin A5 also forms a two
dimensional shield on cell membranes and has anticoagulant effects. Whether these
mechanisms contribute to the beneficial effects observed in this study cannot be
excluded. This thesis provides encouraging evidence for annexin A5 to be a potential
new therapeutic treatment in the management of sepsis and septic shock.
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